PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

about

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.

P2860

Q55262681-57CFEAE6-0230-430B-9C3D-DFEC873504A2 Q55435506-9E4414AA-53D9-4F05-8740-EF7225618F87

P2860

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Item

http://www.wikidata.org/entity/Q48008350

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

PI3K Inhibition Reduces Mammar ...... munity and Anti-PD1 Responses.

@en

PI3K Inhibition Reduces Mammar ...... munity and Anti-PD1 Responses.

@nl

type

Item

label

PI3K Inhibition Reduces Mammar ...... munity and Anti-PD1 Responses.

@en

PI3K Inhibition Reduces Mammar ...... munity and Anti-PD1 Responses.

@nl

prefLabel

PI3K Inhibition Reduces Mammar ...... munity and Anti-PD1 Responses.

@en

PI3K Inhibition Reduces Mammar ...... munity and Anti-PD1 Responses.

@nl

P1476

PI3K Inhibition Reduces Mammar ...... munity and Anti-PD1 Responses.

@en

P2093

Andrew C Johnson

http://www.w3.org/2001/XMLSchema#string

Ann Richmond

http://www.w3.org/2001/XMLSchema#string

Anna E Vilgelm

http://www.w3.org/2001/XMLSchema#string

Colt McClain

http://www.w3.org/2001/XMLSchema#string

Ingrid A Mayer

http://www.w3.org/2001/XMLSchema#string

Jinming Yang

http://www.w3.org/2001/XMLSchema#string

Jiqing Sai

http://www.w3.org/2001/XMLSchema#string

Mark C Kelley

http://www.w3.org/2001/XMLSchema#string

Melinda Sanders

http://www.w3.org/2001/XMLSchema#string

Nicole Lavender

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis

The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

The blockade of immune checkpoints in cancer immunotherapy

Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

P304

3371-3384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-16-2142

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Harold L. Moses

Gregory Daniel Ayers

Mark R. Boothby

P577

2016-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28003307

http://www.w3.org/2001/XMLSchema#string

P932

5479746

http://www.w3.org/2001/XMLSchema#string

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

about

P2860

P2860

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932